Correct Answer: D. Tamoxifen
Tamoxifen is a selective estrogen receptor modulator (SERM) that acts as a competitive antagonist at estrogen receptors in breast tissue, making it the gold standard for estrogen receptor-positive (ER+) breast cancer. In hormone-dependent breast cancer, malignant cells proliferate in response to circulating estrogen. Tamoxifen binds to estrogen receptors with high affinity but does not activate the receptor's transcriptional machinery in breast tissue, thereby blocking estrogen-mediated growth signals. It is used both as adjuvant therapy (post-surgery) and in metastatic disease. The typical dose is 20 mg daily for 5–10 years. Tamoxifen also has partial agonist activity in endometrium and bone, which explains its side effects (endometrial hyperplasia, thromboembolism) but also its benefit in reducing fracture risk. In the Indian context, tamoxifen remains the first-line hormonal agent for premenopausal women with ER+ breast cancer, as per NCCN and Indian oncology guidelines. Aromatase inhibitors (letrozole, anastrozole) are preferred in postmenopausal women. Tamoxifen's efficacy in reducing breast cancer mortality by ~30% over 5 years is well-established in landmark trials (EBCTCG meta-analysis).
Why the other options are wrong
A. Adriamycin — Adriamycin (doxorubicin) is a chemotherapy agent (anthracycline), not a hormonal therapy. It is used in combination chemotherapy regimens (e.g., AC, FAC) for breast cancer regardless of hormone receptor status. It does not target estrogen-dependent pathways and is not selective for ER+ disease. NBE may trap students who confuse chemotherapy with hormonal therapy. B. Estrogen — Administering exogenous estrogen to an estrogen-dependent breast cancer patient would accelerate tumor growth, not inhibit it. This is a classic NBE trap: students may confuse hormone replacement therapy (used in menopausal symptoms) with cancer treatment. Estrogen is contraindicated in ER+ breast cancer. C. Clomiphene citrate — Clomiphene citrate is a selective estrogen receptor modulator used for infertility (ovulation induction in anovulatory women), not for breast cancer treatment. Although it is an SERM like tamoxifen, it has weak antagonist activity in breast tissue and is not used oncologically. Its primary action is at the hypothalamic–pituitary axis, not breast cancer cells.
High-Yield Facts
- Tamoxifen is a SERM that acts as an estrogen receptor antagonist in breast tissue, blocking ER+ cancer cell proliferation.
- ER+ breast cancer accounts for ~70% of all breast cancers in India and is hormone-dependent; tamoxifen is first-line for premenopausal women.
- Tamoxifen dosing: 20 mg daily for 5–10 years; reduces breast cancer mortality by ~30% (EBCTCG meta-analysis).
- Side effects of tamoxifen include endometrial hyperplasia/cancer, venous thromboembolism, and hot flushes; regular gynecological surveillance is mandatory.
- Aromatase inhibitors (letrozole, anastrozole) are preferred in postmenopausal women with ER+ breast cancer; tamoxifen is reserved for premenopausal or those intolerant to AIs.
Mnemonics
SERM in Breast Cancer Selective Estrogen Receptor Modulator = Tamoxifen blocks estrogen in breast, agonist in bone/endometrium. Use when you see 'hormone-dependent breast cancer' + need to block estrogen. TAM = Tamoxifen Antagonizes Mammary growth Quick recall: TAM = Tamoxifen Antagonizes Mammary (breast) cancer. Antagonist in breast tissue = blocks ER+ cancer.
NBE Trap
NBE pairs estrogen (option B) with breast cancer to trap students who confuse hormone replacement therapy with cancer treatment. Students may also conflate clomiphene (another SERM) with tamoxifen, missing the oncological context.
Clinical Pearl
In Indian breast cancer clinics, a premenopausal woman with ER+ breast cancer presenting 2 years post-surgery with rising tumor markers is immediately started on tamoxifen 20 mg daily. If she develops endometrial bleeding or thromboembolism, switching to an aromatase inhibitor (with ovarian suppression) is the next step—this sequence is standard in Indian oncology practice.
_Reference: Bailey & Love Ch. 52 (Breast Surgery); Harrison Ch. 375 (Breast Cancer); Robbins Ch. 23 (Neoplasia)_